Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 2/20 | 0.46 |
| ▸ | ECE1 | P42892 | 1/20 | 0.44 |
| ▸ | GLP1R | P43220 | 1/20 | 0.44 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.44 |
| ▸ | VIPR2 | P41587 | 5/20 | 0.44 |
| ▸ | VIPR1 | P32241 | 3/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.43 |
| ▸ | PTH1R | Q03431 | 2/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4096715 | 0.97 | REN (0.43) | RENECE1GLP1RMUS81VIPR2 | |
| SCHEMBL4089292 | 0.95 | OPRM1 (0.48) | RENECE1GLP1RMUS81VIPR1 | |
| SCHEMBL4088339 | 0.93 | KISS1R (0.49) | VIPR2VIPR1KISS1R | |
| SCHEMBL4082674 | 0.92 | OPRM1 (0.46) | RENECE1GLP1RMUS81VIPR2 | |
| SCHEMBL4087521 | 0.92 | OPRM1 (0.49) | ECE1GLP1RMUS81VIPR2VIPR1 | |
| SCHEMBL13723083 | 0.92 | VIPR1 (0.45) | RENECE1GLP1RMUS81VIPR2 | |
| SCHEMBL4082481 | 0.92 | OPRM1 (0.45) | RENECE1GLP1RMUS81VIPR1 | |
| SCHEMBL4088444 | 0.90 | KISS1R (0.47) | GLP1RVIPR2VIPR1KISS1R | |
| SCHEMBL4082718 | 0.90 | VIPR1 (0.45) | ECE1GLP1RMUS81VIPR2VIPR1 | |
| SCHEMBL13723783 | 0.89 | GLP1R (0.42) | ECE1GLP1RMUS81VIPR2VIPR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076285-B2 | Lysobactin amides | AICURIS GMBH & CO. KG (DE) | 2011-12-13 | — | — | US | disclosed |
| US-20090203582-A1 | LYSOBACTIN AMIDES | BAYER HEALTHCARE AG (DE) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203582-A1 | LYSOBACTIN AMIDES | AADAT, HAMP, DLST | REN 1728/4885ECE1 3037/4885GLP1R 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.